Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11


Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis.

Sarva H, Henchcliffe C.

Ther Adv Neurol Disord. 2016 Nov;9(6):462-473. Epub 2016 Oct 3. Review.


Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.

Chaudhry IB, Husain N, Drake R, Dunn G, Husain MO, Kazmi A, Hamirani MM, Rahman R, Stirling J, Deakin W.

Ther Adv Psychopharmacol. 2014 Jun;4(3):110-6. doi: 10.1177/2045125313511487.


Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Collerton D, Taylor JP.

Future Neurol. 2013 Jul;8(4):433-444.


Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Meireles J, Massano J.

Front Neurol. 2012 May 25;3:88. doi: 10.3389/fneur.2012.00088. eCollection 2012.


Parkinson's psychosis.

Zahodne LB, Fernandez HH.

Curr Treat Options Neurol. 2010 May;12(3):200-11. doi: 10.1007/s11940-010-0072-y.


Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Zahodne LB, Fernandez HH.

Drugs Aging. 2008;25(8):665-82. Review.


Visual hallucinatory syndromes: past, present, and future.

Ffytche DH.

Dialogues Clin Neurosci. 2007;9(2):173-89.


Psychosis in Parkinson's disease.

Thanvi BR, Lo TC, Harsh DP.

Postgrad Med J. 2005 Oct;81(960):644-6. Review.


Neuropsychiatric non-motor aspects of Parkinson's disease.

Thanvi BR, Munshi SK, Vijaykumar N, Lo TC.

Postgrad Med J. 2003 Oct;79(936):561-5. Review.


Hallucinosis in idiopathic Parkinson's disease.

Graham JM, Grünewald RA, Sagar HJ.

J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):434-40.

Supplemental Content

Support Center